News & Events

Disc Presents Positive Initial Data from Phase 2 BEACON Trial of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP) at European Hematology Association (EHA) 2023 Congress

Consistent and dose-dependent reductions of protoporphyrin IX (PPIX), the disease-causing metabolite in EPP, were observed in patients treated with bitopertin Patients reported significant improvements in sunlight tolerance and measures of quality-of-life Bitopertin was well-tolerated, with no

More News

Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Steve Caffé, MD as Chief Regulatory Officer

Dr. Steve Caffé is an accomplished industry executive with over 25 years of expertise in global product development and regulatory affairs WATERTOWN,...

Disc Medicine Reports Second Quarter 2024 Financial Results and Provides Business Update

Presented positive data for all three programs at the European Hematology Association (EHA) 2024 Congress; demonstrated potential efficacy for bitopertin in erythropoietic...

Disc Medicine Announces Underwritten Offering of Common Stock

WATERTOWN, Mass., June 14, 2024 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery,...